DDInter1295 DDInter1376
Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Nimodipine {u} (Compound) resembles {v} (Compound) Nisoldipine
Nimodipine {u} (Compound) binds {v} (Gene) CACNB3
Nimodipine {u} (Compound) upregulates {v} (Gene) WIF1
Nimodipine {u} (Compound) is included by {v} (Pharmacologic Class) Calcium Channel Antagonists
Nimodipine {u} (Compound) causes {v} (Side Effect) Hyperhidrosis
Nimodipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ticagrelor
Nimodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nilotinib
Nimodipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bexarotene
Nimodipine {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Nimodipine (Compound) resembles Nisoldipine (Compound)
Nimodipine (Compound) binds CACNB3 (Gene)
Nimodipine (Compound) upregulates WIF1 (Gene)
Nimodipine (Compound) is included by Calcium Channel Antagonists (Pharmacologic Class)
Nimodipine (Compound) causes Hyperhidrosis (Side Effect)
Nimodipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib
Nimodipine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene
Nimodipine may lead to a major life threatening interaction when taken with Clarithromycin